Literature DB >> 15587919

Transferrin-oligomers as potential carriers in anticancer drug delivery.

Ching-Jou Lim1, Wei-Chiang Shen.   

Abstract

PURPOSE: To investigate if the cross-linking of transferrin receptor (TfR) induced by Tf-oligomers alters the endocytosis of receptor-ligand complexes in cultured tumor cells and hence increases intracellular drug release.
METHODS: An average of 3.5 Tf molecules per aggregate were cross-linked either by using homobifunctional linker (1, 11-bis-maleimidotetraethyleneglycol) [Tf(3.5-BM(PEO)4)] or heterobifunction linker [succinimidyl 4-(-p-maleimidophenyl)-butyrate] (Tf(3.5-SMPB)). Cell surface binding and competition experiments with 125I-Tf for TfR binding were studied to demonstrate that Tf-oligomers maintain specificity of the TfR-binding. To determine the degradation of Tf-oligomers in TfR-mediated endocytosis, cultured tumor cells were pulsed for 15 min with 125I-Tf-oligomers and chased for 2 h at 37 degrees C in the presence of excess unlabeled Tf. The chase medium was subjected to TCA precipitation to separate the intact and degraded Tf. To investigate if the alteration of TfR-trafficking facilitates the intracellular release of the drug from the Tf-conjugated form, methotrexate (MTX) was conjugated to Tf-oligomer (Agg-Tf-MTX) and its antiproliferative activity was compared with monomeric-Tf-MTX (Mono-Tf-MTX) in human colon carcinoma (Caco-2) cells, human breast adenocarcinoma (MCF-7) cells, wild-type Chinese hamster ovary (CHO) cells, and MTX-resistant CHO (CHO-MTX-RII) cells.
RESULTS: TfR-mediated degradation of Tf-oligomers was higher than that of monomeric Tf in both Caco-2 and MCF-7 cells. The IC50 of Agg-Tf-MTX was lower than that of Mono-Tf-MTX in both tumor cell lines. The IC50 of MTX and Mono-Tf-MTX in CHO-MTX-RII cells was higher than that in wild-type CHO cells, whereas the Agg-Tf-MTX was almost identical in both the resistant and wild-type cells.
CONCLUSIONS: Cross-linking of TfR induced by oligomeric Tf binding alters the intracellular trafficking of Tf-TfR complexes, redirects them out of the recycling pathway, and targets them to intracellular degradation in cultured tumor cells. The alteration of TfR-trafficking facilitates the intracellular release of the drug from the Tf-conjugated form. Consequently, Agg-Tf-MTX is more effective than Mono-Tf-MTX as a TfR-mediated antiproliferative agent in tumor cells, as well as in MTX-resistant transport deficient cells. Therefore, Tf-oligomers are potentially effective TfR-targeting carriers for intracellular delivery of anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15587919     DOI: 10.1023/b:pham.0000048188.69785.94

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  40 in total

1.  Receptor-mediated targeted drug or toxin delivery.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-02-02       Impact factor: 15.470

2.  [Anemia in malignant tumor diseases. I. Tumor-induced loss of transferrin and its relation to tumor size and degree of malignancy in the rat model].

Authors:  E Aulbert
Journal:  Nuklearmedizin       Date:  1989-10       Impact factor: 1.379

3.  Studies of 125I trace labeling of immunoglobulin G by chloramine-T.

Authors:  S Sonoda; M Schlamowitz
Journal:  Immunochemistry       Date:  1970-11

4.  Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats.

Authors:  C Q Xia; J Wang; W C Shen
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

Review 5.  Dihydrofolate reductase as a therapeutic target.

Authors:  B I Schweitzer; A P Dicker; J R Bertino
Journal:  FASEB J       Date:  1990-05       Impact factor: 5.191

6.  Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells.

Authors:  W F Flintoff; S V Davidson; L Siminovitch
Journal:  Somatic Cell Genet       Date:  1976-05

7.  Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.

Authors:  Markéta Jelínková; Jirí Strohalm; Tomás Etrych; Karel Ulbrich; Blanka Ríhová
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

Review 8.  Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.

Authors:  Michael Weaver; Douglas W Laske
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

9.  Internalization and rapid recycling of macrophage Fc receptors tagged with monovalent antireceptor antibody: possible role of a prelysosomal compartment.

Authors:  I Mellman; H Plutner; P Ukkonen
Journal:  J Cell Biol       Date:  1984-04       Impact factor: 10.539

10.  Beta-very low density lipoprotein is sequestered in surface-connected tubules in mouse peritoneal macrophages.

Authors:  J N Myers; I Tabas; N L Jones; F R Maxfield
Journal:  J Cell Biol       Date:  1993-12       Impact factor: 10.539

View more
  5 in total

1.  Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles.

Authors:  Deboshri Banerjee; Allen P Liu; Neil R Voss; Sandra L Schmid; M G Finn
Journal:  Chembiochem       Date:  2010-06-14       Impact factor: 3.164

Review 2.  Endocytic mechanisms for targeted drug delivery.

Authors:  Lisa M Bareford; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

3.  Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells.

Authors:  Daniel P Ferris; Jie Lu; Chris Gothard; Rolando Yanes; Courtney R Thomas; John-Carl Olsen; J Fraser Stoddart; Fuyuhiko Tamanoi; Jeffrey I Zink
Journal:  Small       Date:  2011-05-19       Impact factor: 13.281

4.  Inhibition of transferrin iron release increases in vitro drug carrier efficacy.

Authors:  Bert J Lao; Wen-Lin P Tsai; Foad Mashayekhi; Edward A Pham; Anne B Mason; Daniel T Kamei
Journal:  J Control Release       Date:  2006-12-08       Impact factor: 9.776

5.  Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins.

Authors:  Dennis J Yoon; David S H Chu; Christopher W Ng; Edward A Pham; Anne B Mason; David M Hudson; Valerie C Smith; Ross T A MacGillivray; Daniel T Kamei
Journal:  J Control Release       Date:  2008-10-21       Impact factor: 9.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.